false
0001736243
0001736243
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
November 12, 2026
Date of report (Date of earliest event reported)
ACURX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
| Delaware | |
001-40536 | |
82-3733567 |
(State or other jurisdiction of
incorporation or organization) | |
(Commission File Number) | |
(I.R.S. Employer
Identification Number) |
| 259 Liberty Avenue, Staten Island, NY |
10305 |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (917) 533-1469
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Stock, par value $0.001 per share |
|
ACXP |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 12, 2026, Joseph C. Scodari, a member
of the Board of Directors (the “Board”) of Acurx Pharmaceuticals, Inc. (the “Company”) since 2021, provided the
Company with notice of his intention to retire from the Board, effective November 13, 2026. Mr. Scodari’s decision did not result
from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Scodari’s
retirement follows years of dedicated service, leadership and significant contributions to the Company and to the healthcare and pharmaceutical
industries. Following his retirement from the Board, Mr. Scodari has agreed to continue to serve the Company as a corporate advisor.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ACURX PHARMACEUTICALS, INC. |
| |
|
|
| Date: November 13, 2026 |
By: |
/s/ David P. Luci |
| |
|
David P. Luci |
| |
|
President and Chief Executive Officer |
